MedTrace Logo

Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis

NCT04955951 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-08-23

No results posted yet for this study

Summary

Non-atopic dermatitis (NAD) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. It is usually seen in childhood, but can onset within or persist into adulthood.

Conditions

  • Chronic Atopic Dermatitis

Interventions

DEVICE

polarized light

A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute

DRUG

Topical corticosteroid ointment

corticosteroid 1 %.

Sponsors & Collaborators

  • Ahram Canadian University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2021-09-15
Completion
2022-01-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04955951 on ClinicalTrials.gov